Cha AI Healthcare Co (025620) Fair Value & Analysis
Consumer Defensive · KR · Market cap 79.9B KRW
Fair value as of: Jul 22, 2026
From 8 valuation models · updated 19 days ago
Share price −31.3% over the past month.
Below-average quality, and screening another 78% overvalued on our models.
What matters now
- The price sits above even our optimistic bull case (1,357 KRW). The favourable scenario is already priced in.
- Weak quality (18/100) and above fair value at the same time, the margin of safety is missing on both counts.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Jul 22, 2026.
How to read this chart
60‑month range 3,350 KRW – 43,700 KRW · fair‑value band 814.21 KRW – 1,357 KRW · the 4,850 KRW price screens above the 1,086 KRW fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Jul 22, 2026.
Analysis
Cha AI Healthcare Co (025620) currently trades at 4,850 KRW, while our model-based Fair Value estimate is 1,086 KRW, implying the stock looks roughly 77.6% overvalued today. The Quality Score stands at 18/100 (below-average quality), in the Consumer Defensive sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: medium).
Over the trailing twelve months, Cha AI Healthcare Co generated revenue of 7.5B KRW at a net margin of -12.2%. Revenue grew 10.6% year over year. It earns a return on equity of -1.8%. Net debt stands at 2.2B KRW. Fundamentals as of Jul 22, 2026
Our scenario range runs from 814.21 KRW (bear case) to 1,357 KRW (bull case); at 4,850 KRW, the current price sits above that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 75% below its 52-week high, currently below its 200-day average. For context, the median of 10 Consumer Defensive peers we cover trades at -26% fair-value upside, at -78%, 025620 screens richer than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 8 models by family
Widest divergence: DCF Models (3,306 KRW) versus Earnings-Based (624.40 KRW). Highest evidence: Growth-Adj P/E (68).
Notify me when 025620 reaches fair value
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Jul 22, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 25 · Market factors (momentum, volatility) 19
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
Cha AI Healthcare Co., Ltd., together with its subsidiaries, manufactures and distributes cosmetic products in South Korea.
Full company description
Cha AI Healthcare Co., Ltd., together with its subsidiaries, manufactures and distributes cosmetic products in South Korea. The company offers facial care products, including masks/packs, skin/toner/mist, pads/patches, ampoules/serums/essence, lotion/emulsion, creams/gels, cleansing/peeling, sun care, and beauty accessories products; skin cells/texture, moisture/moisturizing, whitening/brightening, and sensitive/calm care products; nutritional/elasticity/anti-aging care products; and UV protection care products. The company was formerly known as Jayjun Cosmetic Co., Ltd. and changed its name to Cha AI Healthcare Co., Ltd. in December 2025. Cha AI Healthcare Co., Ltd. was founded in 1972 and is headquartered in Seoul, South Korea.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Cha AI Healthcare Co reported revenue of 7.3B KRW in FY2025 versus 20.5B KRW in FY2021, a compound −22.8%/yr. Reported net income was 1.4B KRW in FY2025.
025620 screens 78% overvalued. Compare with The Procter & Gamble Company →
Peer Group
Household & Personal Products · 244 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
VALUE 0: the price sits above our fair-value range.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.
Similar stocks
10 more Household & Personal Products stocks, each showing price versus our Fair Value estimate (as of Jul 22, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| The Procter & Gamble Company PG | $146.80 | $108.16 | -26% |
| Unilever PLC ULN | 1,080 MXN | 1,273 MXN | +18% |
| Hindustan Unilever Limited HINDUNILVR | ₹2,144 | ₹1,000 | -53% |
| Essity AB ESSITYA | kr 279.00 | kr 250.02 | -10% |
| Godrej Consumer Products Limited GODREJCP | ₹1,088 | ₹367.64 | -66% |
| Marico Limited MARICO | ₹846.75 | ₹233.05 | -72% |
| APR Co 278470 | 375,000 KRW | 151,222 KRW | -60% |
| Dabur India Limited DABUR | ₹429.45 | ₹181.60 | -58% |
| Kimberly-Clark de México, S. A. B. de C. V., KIMBERA | 38.07 MXN | 50.09 MXN | +32% |
| PT Unilever Indonesia Tbk UNVR | 1,730 IDR | 1,934 IDR | +12% |
Compare Cha AI Healthcare Co with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Consumer Defensive stocks →
Frequently asked questions
Is Cha AI Healthcare Co (025620) overvalued or undervalued?
What is the fair value of 025620?
What is the quality score of 025620?
What is the revenue of Cha AI Healthcare Co (025620)?
What is the net profit margin of 025620?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track Cha AI Healthcare Co and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.